Project Grant R21CA292333
Award Date
6/1/25
Completion Date
5/31/27
Dollars Obligated
$235K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Milwaukee, WI 53226, USA
Similar Awards
This $1,261,143 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Indiana University to exploit metabolic reprogramming of prostate cancer for new therapeutics. The key research tasks include: Determining the mechanism of p53 expression activation following loss of GCN2 in prostate cancer cell lines. Evaluating the effects on gene expression and metabolism when p53 is lost in GCN2-inhibited prostate...
This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), provides $400,000 to Nuago Therapeutics Inc. to develop a novel, RNA interference-based therapeutic for the treatment of prostate cancer. The goal is to develop an "NU002" therapeutic, delivered via lipopolyplex nanoparticles, that utilizes short interfering RNA molecules derived from CAG trinucleotide repeat sequences to target and silence genes essential for prostate...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is to investigate the role of the SEC61 protein complex in mediating resistance to immunotherapy in glioblastoma (GBM), an aggressive brain cancer. The $577,634 award to Northwestern University will fund a 5-year research project to understand how overexpression of SEC61 allows GBM tumors to evade T cell-mediated immunotherapies. The study aims to characterize SEC61 as a therapeutic...
The federal Project Grant award of $433,157 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Endeavor Health Clinical Operations, Northshore University Healthsystem Research Institute Division, supports research investigating the role of lipid-rich macrophages in the tumor microenvironment of prostate cancer. The study aims to determine whether altering the activity of certain enzymes and proteins involved in lipid metabolism and inflammatory signaling in these...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $692,072 to The University of Texas Southwestern Medical Center to develop a novel theranostic platform for managing aggressive subtypes of prostate cancer. The key products and services to be delivered under this 5-year grant include: Synthesizing PSMA-targeted poly(amidoamine) (PAMAM) dendrimer-based theranostic agents that can enable specific targeting, PET/CT...
The federal Project Grant award of $371,719 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research at the University of Pennsylvania to investigate the role of the epigenetic modifier NSD2 in prostate cancer progression. The primary aims are to gain deeper mechanistic understanding of how NSD2 influences the chromatin landscape to facilitate the assembly of the androgen receptor (AR) enhanceosome complex, and to evaluate...
This $581,087 federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research by the University of Chicago to develop genetically-engineered Bifidobacterium bacteria that can deliver a novel human IL-2 protein to the tumor microenvironment. The goal is to enhance the effects of radiotherapy and immunotherapy for treating metastatic pancreatic ductal adenocarcinoma, a difficult-to-treat cancer. Preliminary data indicates this approach can...
This $627,474 federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Dana-Farber Cancer Institute, Inc. (DFCI) aims to utilize epigenomic methods and signatures to inform the understanding of lineage plasticity, including treatment-emergent neuroendocrine prostate cancer (NEPC), and to use epigenomic signatures to predict enzalutamide resistance. Specifically, the project will endeavor to identify clinically relevant NEPC...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports Duke University's research to develop novel immunotherapies using optimized tumor cell-penetrating antibodies. The primary objective is to translate these antibody-based therapies into the clinic to effectively combat aggressive, mutation-driven human cancers. Specifically, the researchers have engineered new IgG4 antibodies that incorporate a PIGR-binding peptide, enabling them...
The National Cancer Institute (NCI) awarded a $422,874 Project Grant under CFDA 93.394 - Cancer Detection and Diagnosis Research to the University of Connecticut Health Center (UCHC) to develop a well-defined in vitro model that mimics the bone-tumor microenvironment of metastatic prostate cancer. The goal is to create a flexible 3D bioprinted tumor microenvironment model that can serve as a preclinical screening platform to enhance the development of novel therapeutic agents. As part of this...